Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine in heart transplant recipients
NCT03619187Phase 3Withdrawn
- Sponsor
- Amgen
- Start
- Nov 2018
- Primary completion
- Feb 2020
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of ivabradine in tachycardia, sponsored by Amgen. Primary endpoint: Peak Oxygen Consumption at Week 16. Planned start Nov 2018; status: withdrawn.
02
Drugs
ivabradine
03
Conditions
tachycardia
Beyond the preview
Go deeper on NCT03619187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03619187.